MEDIA RELEASE

New Material Kills E. Coli Bacteria in 30 Seconds

Singapore, June 3, 2016 – Every day, we are exposed to millions of harmful bacteria that can cause infectious diseases, such as the E. coli bacteria. Now, researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have developed a new material that can kill the E. coli bacteria within 30 seconds. This finding has been published in the peer-reviewed journal, Small.

“The global threat of drug-resistant bacteria has given rise to the urgent need for new materials that can kill and prevent the growth of harmful bacteria. Our new antimicrobial material could be used in consumer and personal care products to support good personal hygiene practices and prevent the spread of infectious diseases,” said IBN Executive Director, Professor Jackie Y. Ying.

Triclosan, a common ingredient found in many products such as toothpastes, soaps and detergents to reduce or prevent bacterial infections, has been linked to making bacteria resistant to antibiotics and adverse health effects. The European Union has restricted the use of triclosan in cosmetics1, and the U.S. Food and Drug Administration is conducting an on-going review of this ingredient2.

Driven by the need to find a more suitable alternative, IBN Group Leader Dr Yugen Zhang and his team synthesized a chemical compound made up of molecules linked together in a chain. Called imidazolium oligomers, this material can kill 99.7% of the E. coli bacteria within 30 seconds aided by its chain-like structure, which helps to penetrate the cell membrane and destroy the bacteria. In contrast, antibiotics only kill the bacteria without destroying the cell membrane. Leaving the cell structure intact allows new antibiotic-resistant bacteria to grow.

“Our unique material can kill bacteria rapidly and inhibit the development of antibiotic-resistant bacteria. Computational chemistry studies supported our experimental findings that the chain-like compound works by attacking the cell membrane. This material is also safe for use because it carries a positive charge that targets the more negatively charged bacteria, without destroying red blood cells,” said Dr Zhang.

1 Scientific Committee on Consumer Safety of the European Commission: “Opinion on Triclosan Antimicrobial Resistance: 5.1 Triclosan in cosmetics”.
2 U.S. Food and Drug Administration website: “Triclosan: What Consumers Should Know”.

A*STAR Patent Power Award 2009 and 2010
Singapore HEALTH Award (Platinum) 2012, (Gold) 2008 and 2010
A member of A*STAR’s Biomedical Sciences Institutes (Co. Reg. No. 199702109N)
The imidazolium oligomers come in the form of a white powder that is soluble in water. The researchers also found that once this was dissolved in alcohol, it formed gels spontaneously. This material could be incorporated in alcoholic sprays that are used for sterilization in hospitals or homes.

*E. coli* is a type of bacteria found in the intestines of humans and animals, and some strains can cause severe diarrhea, abdominal pain and fever. Such infection is contagious and can spread through contaminated food or water, or from contact with people or animals. Good hygiene practices and proper food handling can prevent *E. coli* infections.

Besides *E. coli*, IBN’s material was also tested against other common strains of antibiotic-resistant bacteria and fungi, such as *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Candida albicans*. These pathogens can cause conditions ranging from skin infections to pneumonia and toxic shock syndrome. Our material was able to kill 99.9% of these microbes within two minutes.

IBN’s ultrafast bacteria-killing material could therefore be a potent new weapon against drug-resistant microbes.

**Reference:**


**Images:**

Image 1: IBN researchers who developed the new antimicrobial material that can kill *E. coli* bacteria within 30 seconds (from left: Dr Yuan Yuan, Dr Siti Nurhanna Riduan and Dr Yugen Zhang). © Institute of Bioengineering and Nanotechnology
Image 2: A microscopic image of the *E. coli* bacteria. © Institute of Bioengineering and Nanotechnology

Image 3: A microscopic image of the *E. coli* bacteria after it has been destroyed by the antimicrobial material. © Institute of Bioengineering and Nanotechnology

**Media Contacts:**

Elena Tan
Phone: +65 6824 7032
Email: elenatan@ibn.a-star.edu.sg

Nidyah Sani
Phone: +65 6824 7005
Email: nidyah@ibn.a-star.edu.sg

**About the Institute of Bioengineering and Nanotechnology (IBN)**

The Institute of Bioengineering and Nanotechnology (IBN) is the world’s first bioengineering and nanotechnology research institute. Established in 2003, IBN’s mission is to conduct multidisciplinary research across science, engineering, and medicine for breakthroughs to improve healthcare and quality of life. IBN’s research activities are focused on Nanomedicine, Synthetic Biosystems, Biodevices and Diagnostics, and Green Chemistry and Energy. The Institute has published over 1,100 papers in leading scientific journals, filed over 550 active patents and patent applications on its inventions, and established 10 spin-off companies. To nurture young research talents, IBN runs a Youth Research Program that offers students research attachment opportunities and exposure to biomedical research.

For more information about IBN, please visit www.ibn.a-star.edu.sg.
About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and Research Institutes, the wider research community and industry. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities primarily located in Biopolis and Fusionopolis.

For more information on A*STAR, please visit www.a-star.edu.sg.